ISSN: 2161-0681

臨床病理学ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • シェルパ・ロミオ
  • Jゲートを開く
  • Genamics JournalSeek
  • ジャーナル目次
  • ウルリッヒの定期刊行物ディレクトリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

Macrophage Inflammatory Protein-1α (MIP-1 α) in Hepatitis C Virus- Related Hepatocellular Carcinoma: Relation to Clinical Staging and Tumour Angiogenesis

Hoda A. El Aggan, Myriam A. Helmy, Nevine M.F. El Deeb, Ahmed E. Zeid and Mohamed F. A. Yehia

Abstract
Study background: Hepatitis C virus (HCV) is a major risk factor for the development of hepatocellular
carcinoma (HCC), however, the mechanism of hepatocarcinogenesis in HCV infection is still undefined. Chemokines,
which induce leukocyte migration and activate inflammatory/immune responses, have recently been implicated in the
regulation of tumour growth. This work was designed to study the role of macrophage inflammatory protein-1α (MIP-
1α), a potent macrophage chemo-attractant, in the development and progression of HCV-related HCC.
Methods: Thirty patients with HCV-related cirrhosis (15 patients with HCC who underwent surgical hepatic
resection and 15 patients without HCC) and 15 healthy subjects were enrolled in the study. Immunohistochemical
staining of HCC and adjacent non-neoplastic liver tissue was performed using antibodies against MIP-1α, CD68 [for
assessment of tumour-associated macrophage (TAM) count] and CD105 [for determination of microvessel density
(MVD)]. Pre-operative serum MIP-1α levels were measured using enzyme linked immunosorbant assay kit.
Results: HCV-related HCCs showed significantly higher MIP-1α expression, CD68+ TAM count and CD105-MVD
compared with adjacent non-neoplastic liver tissue. Serum MIP-1α levels were significantly higher in patients with and
without HCC than in healthy subjects and in HCC patients than in patients without HCC. The sensitivity and specificity
of serum MIP-1α in discriminating cirrhotic patients with and without HCC were 100% and 93.3% respectively at a
cut-off value of 17.5 pg/ml. The MIP-1α expression in HCCs showed positive correlations with serum MIP-1α levels;
tumour size, stage and histopathological grade; and intratumoural CD68+ TAM count and CD105-MVD. Moreover,
CD68+ TAM count had direct correlation with CD105-MVD in HCC.
Conclusion: MIP-lα plays an important role in the development and progression of HCC in chronic HCV infection,
possibly through recruitment of macrophages into tumour microenvironment and fostering tumour angiogenesis. MIPlα
may also serve as a potential serum biological marker and a useful therapeutic target in HCV-related HCC.